Could a monthly shot replace weekly diabetes injections?
NCT ID NCT07677891
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether people with type 2 diabetes can switch from a weekly injection of dulaglutide to a once-monthly shot called PG-102. The trial involves 60 adults whose blood sugar is well-controlled on dulaglutide. Researchers will compare blood sugar levels and safety over 32 weeks to see if the monthly option works just as well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PG-102 (a GLP-1 and GLP-2 fusion protein)
- What this could lead to
- If successful, this could offer people with type 2 diabetes a convenient once-monthly injection instead of a weekly one, making blood sugar control easier to maintain.
- What could go wrong
- This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The new drug may not control blood sugar as well as the current weekly option, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?